

# Alon Altman

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5432489/alon-altman-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58  
papers

1,365  
citations

17  
h-index

36  
g-index

66  
ext. papers

1,864  
ext. citations

2.5  
avg, IF

4.25  
L-index

#	Paper	IF	Citations
58	Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS <sup>®</sup> ) Society recommendations--Part I. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 313-22	4.9	263
57	Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS <sup>®</sup> ) Society recommendations--Part II. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 323-32	4.9	246
56	Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> , 29, 651-668	3.5	216
55	International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 221, 237.e1-237.e11	6.4	57
54	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. <i>Modern Pathology</i> , <b>2013</b> , 26, 1255-63	9.8	38
53	Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 268-74	4.9	35
52	Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 1006-12	3.5	33
51	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPERitoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS <sup>®</sup> ) Society Recommendations - Part I: Preoperative and intraoperative management. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 2292-2310	3.6	33
50	Maternal age-related rates of gestational trophoblastic disease. <i>Obstetrics and Gynecology</i> , <b>2008</b> , 112, 244-50	4.9	32
49	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPERitoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS <sup>®</sup> ) Society Recommendations - Part II: Postoperative management and special considerations. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 2311-2323	3.6	28
48	The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples. <i>PLoS Genetics</i> , <b>2017</b> , 13, e1006707	6	27
47	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 148-54	4.9	26
46	Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center. <i>International Journal of Gynecological Cancer</i> , <b>2015</b> , 25, 1616-22	3.5	23
45	Architectural patterns of ovarian/pelvic high-grade serous carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2012</b> , 31, 397-404	3.2	23
44	Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. <i>Journal of Medical Genetics</i> , <b>2018</b> , 55, 571-577	5.8	22
43	Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. <i>American Journal of Surgery</i> , <b>2019</b> , 218, 537-550	2.7	19
42	Guidelines for vulvar and vaginal surgery: Enhanced Recovery After Surgery Society recommendations. <i>American Journal of Obstetrics and Gynecology</i> , <b>2020</b> , 223, 475-485	6.4	18

41	Enhanced recovery after surgery: implementing a new standard of surgical care. <i>Cmaj</i> , <b>2019</b> , 191, E469-E475	4.5	16
40	The effects of anemia and blood transfusion on patients with stage III-IV ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2013</b> , 23, 1569-76	3.5	15
39	Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 257-261	4.9	14
38	Pfannenstiel incision closure: a review of current skin closure techniques. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2009</b> , 31, 514-520	1.3	14
37	Examining Survival Outcomes of 852 Women With Advanced Ovarian Cancer: A Multi-institutional Cohort Study. <i>International Journal of Gynecological Cancer</i> , <b>2018</b> , 28, 925-931	3.5	13
36	Hereditary angioedema managed with low-dose danazol and C1 esterase inhibitor concentrate: a case report. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2006</b> , 28, 27-31	1.3	13
35	Impact of Nutrition on Enhanced Recovery After Surgery (ERAS) in Gynecologic Oncology. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	12
34	New approaches to cancer care in a COVID-19 world. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, e339-e340	21.7	12
33	Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival. <i>Obstetrics and Gynecology</i> , <b>2016</b> , 127, 837-847	4.9	12
32	Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2012</b> , 34, 664-72	1.3	11
31	Vacuum assisted wound closures in gynaecologic surgery. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2011</b> , 33, 1031-1037	1.3	10
30	Examining the Effects of Time to Diagnosis, Income, Symptoms, and Incidental Detection on Overall Survival in Epithelial Ovarian Cancer: Manitoba Ovarian Cancer Outcomes (MOCO) Study Group. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 1637-1644	3.5	9
29	Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study. <i>Gynecologic Oncology</i> , <b>2020</b> , 157, 234-244	4.9	8
28	Luteinized Thecomas ("Thecomatosis") with Sclerosing Peritonitis (LTSP): Report of 2 Cases and Review of an Enigmatic Syndrome Associated with a Peritoneal Proliferation of Specialized (vimentin+/keratin+/CD34+) Submesothelial Fibroblasts. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2014</b> , 36, 41-50	1.3	8
27	No. 385-Indications for Pelvic Examination. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2019</b> , 41, 1221-1234	1.3	7
26	Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2012</b> , 34, 558-566	1.3	7
25	Time to surgery and the risk of cancer progression in patients with gynaecologic cancers of the lower genital tract. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2015</b> , 37, 338-44	1.3	6
24	The Canadian Gynaecologic Oncology Perioperative Management Survey: Baseline Practice Prior to Implementation of Enhanced Recovery After Surgery (ERAS) Society Guidelines. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2016</b> , 38, 1105-1109.e2	1.3	6

23	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 647-655	3.5	5
22	A molecular assessment of homing in the tidepool sculpin. <i>Journal of Fish Biology</i> , <b>2003</b> , 62, 623-640	1.9	4
21	Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1748-1756	3.5	4
20	Tubal teratoma causing anti-NMDAR encephalitis. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2014</b> , 36, 1093-1096	1.3	3
19	Postoperative Infection in the Setting of Massive Intraoperative Blood Loss. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2016</b> , 38, 1110-1113	1.3	3
18	Vulvar postoperative care, gestalt or evidence based medicine? A comprehensive systematic review. <i>Gynecologic Oncology</i> , <b>2017</b> , 145, 386-392	4.9	2
17	Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 769-778	4.9	2
16	Low-Risk Gestational Trophoblastic Neoplasia in Manitoba: Experience With Alternating Methotrexate and Dactinomycin. <i>International Journal of Gynecological Cancer</i> , <b>2018</b> , 28, 1448-1452	3.5	2
15	Uterine Inversion as a Result of a Large Prolapsed Carcinosarcoma of the Uterus. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2019</b> , 41, 1181-1184	1.3	1
14	Rate of Appendiceal Metastasis with Non-Serous Epithelial Ovarian Cancer in Manitoba. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2018</b> , 40, 180-185	1.3	1
13	NB85 - Indications de l'examen pelvien. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2019</b> , 41, 1235-1250	1.3	1
12	Paraneoplastic myositis secondary to poorly differentiated serous carcinoma of ovarian/tubal origin. <i>Gynecologic Oncology Reports</i> , <b>2017</b> , 20, 112-114	1.3	1
11	Diagnostic and referral intervals for Manitoba women with epithelial ovarian cancer - the Manitoba Ovarian Cancer Outcomes (MOCO) study group: a retrospective cross-sectional study. <i>CMAJ Open</i> , <b>2017</b> , 5, E116-E122	2.5	1
10	Extra-uterine endometrial stromal sarcoma of the left adnexa and distal ureter: A case report. <i>Gynecologic Oncology Reports</i> , <b>2021</b> , 36, 100702	1.3	1
9	Examining the Selection Criteria of Neoadjuvant Chemotherapy Patients. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2018</b> , 40, 595-603	1.3	0
8	Spontaneous Rupture of an Unscarred Uterus Diagnosed Postpartum: A Case Report. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2015</b> , 37, 1021-4	1.3	0
7	Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5515-5515	2.2	0
6	Cytotoxic capacity of a novel glycosylated antitumor ether lipid in chemotherapy-resistant high grade serous ovarian cancer in vitro and in vivo. <i>Translational Oncology</i> , <b>2021</b> , 14, 101203	4.9	0

5 Gynecologic/Oncology Surgery **2020**, 443-456

4 Response to Multi-Line Chemotherapy in Non-Serous Epithelial Ovarian Cancer. *Journal of Obstetrics and Gynaecology Canada*, **2020**, 42, 1217-1222 1.3

3 The Risk of Postoperative Infectious Complications Following Massive Intraoperative Blood Loss During Gynaecologic Laparotomy: Retrospective Cohort Study. *Journal of Obstetrics and Gynaecology Canada*, **2021**, 43, 19-25 1.3

2 Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman StudyTM. *Current Oncology*, **2022**, 29, 3318-3340 2.8

1 Venous thromboembolic prophylaxis **2022**, 161-175